Navigation Links
Fully dissolvable, temporary stent for opening heart artery blockages
Date:9/17/2013

The Mount Sinai Medical Center is participating in the nationwide ABSORB III clinical trial testing the performance and potential clinical benefits of a fully dissolvable and temporary drug eluting stent to open heart artery blockages. The randomized trial aims to compare the efficiency and safety of Absorb Bioresorbable Vascular Scaffolds (Absorb BVS) in coronary artery disease patients and compare it to the current standard of care drug eluting metal stents.

Absorb BVS is a flexible artery support tube made of a naturally dissolvable material called polylactide. It is inserted by interventional cardiologists minimally invasively during a cardiac catheterization procedure. Absorb BVS works to line the interior of a blocked heart artery to keep it open and restore proper blood flow to the heart. The supportive tube then dissolves into the artery wall within two years.

"Dissolvable stents may be a future game-changer for the way we treat coronary artery disease and heart attack in the United States if proven to show clinical benefit in this nationwide clinical trial," says Samin K. Sharma, MD, Director of Clinical and Interventional Cardiology at The Mount Sinai Medical Center and the Zena and Michael A. Wiener Professor of Medicine at Icahn School of Medicine at Mount Sinai. "The stent is designed to open a blocked heart vessel and eventually dissolve and disappear, leaving no remnants on the heart of a cardiac interventional procedure."

"We look forward to testing this innovative absorbable artery support technology's efficiency and safety at Mount Sinai," says Annapoorna S. Kini, MD, Director of the Cardiac Catheterization Laboratory at The Mount Sinai Medical Center. "Since the stent is designed to completely dissolve into the arterial tissue it may potentially help improve the overall health of a patient's once blocked heart vessel while restoring its natural flexibility and movement."

"Heart disease is still the numb
'/>"/>

Contact: Lauren Woods
lauren.woods@mountsinai.org
212-241-2836
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. How to learn successfully even under stress
2. New beautifully colored long-horned beetle from Yunnan, China
3. Chinese scientists successfully crack the genome of diploid cotton
4. Efforts to develop new drugs that hopefully will never be used
5. Scale-up of a temporary bioartificial liver support system described in BioResearch Open Access
6. Temporary storage for electrons: Natural method of producing hydrogen
7. New compound excels at killing persistent and drug-resistant tuberculosis
8. Stenting dramatically improves treatment access for dialysis patients
9. Drug-coated stents prevent leg amputation
10. Stenting blocked bowel arteries saves lives
11. Global nitrogen availability consistent for past 500 years, linked to carbon levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Canada , August 31, 2015 ... of biometrics technology in government digitization projects to drive ... to a recently published TechSci Research report, " India Biometrics ... India is projected to grow at a ... the market is anticipated on account of extensive use of ...
(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... triggered changes in the type of sperm a male produces, ... The study, published in the Proceedings of the National ... for reproduction influences the sperm of many species of African ... strict monogamy to species where females mate with many males ...
... (Jan. 21, 2009) Finding cures for hearing loss, ... identify people at risk for tuberculosis are goals of ... L.E. Simmons Family Foundation Collaborative Research Fund. The fund, ... diagnose and treat diseases, supports collaboration among researchers at ...
... This month, the City of Newark, Delaware became the ... car to store and provide power for the local ... electricity alone, is specifically designed to store energy and ... the concept, called Vehicle-to-Grid (V2G). With the City of ...
Cached Biology News:The more promiscuous the female, the speedier the sperm 2Texas Medical Center researchers win collaborative grants 2Texas Medical Center researchers win collaborative grants 3Texas Medical Center researchers win collaborative grants 4City of Newark first in nation using cars to power grid 2
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Middle East & Africa Biomedical Sensors ... to their offering. The ... is estimated at $0.84 billion by 2018 at a ... The near future will bring Biomedical sensors that are ...
(Date:8/31/2015)...  US-Australian drug discovery company, Novogen Limited (ASX: ... comprehensive scientific review has identified high value opportunities ... unmet patient need. Novogen is moving as quickly ... to entering into Phase 1 clinical trials with ... Executive Officer, Iain Ross , said that ...
(Date:8/31/2015)... 2015 Trimb Healthcare AB ("Trimb") today announced ... Group BV ("YouMedical"), a Dutch OTC company with operations ... of approximately EUR 16 million, with solid growth and ... ambition is to build a leading international OTC company, ... goal. YouMedical gives us a stronger North European OTC ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Proove Biosciences, ... County Technology Alliance Annual High Tech Awards. , Now in its 22nd year, ... products which drive innovation here, across the nation and around the world. The OC ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... March 6, the Air Force Office of Scientific Research ... Mirkin from Northwestern University. Professor Mirkin is a ... for his development of nanoparticle-based biodetection schemes, the invention ... his contributions to supramolecular chemistry, nanoelectronics, and nanooptics. He ...
... WOODLANDS, Texas, March 20, 2012   Lexicon Pharmaceuticals, ... that the U.S. Food and Drug Administration (FDA) has ... telotristat etiprate (LX1032) for the treatment of carcinoid ... neuroendocrine tumors that usually originate from the gastrointestinal tract ...
... March 20, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... Inc. has received approval from the United States Food ... (ANDA) for Ibandronate 150mg tablets, the generic equivalent to ... product in the second quarter. BONIVA® 150mg tablets had ...
Cached Biology Technology:Air Force Office of Scientific Research hosts nanotechnology pioneer 2Air Force Office of Scientific Research hosts nanotechnology pioneer 3Air Force Office of Scientific Research hosts nanotechnology pioneer 4FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome 2FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome 3FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome 4Watson's Generic BONIVA® 150mg Receives FDA Approval 2
... for rapid, convenient, and efficient native protein ... utilizes a spin column to make handling ... of proteins which were electro-eluted in their ... exchangers, offering high binding capacity fo all ...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... suspension array system, 100-240 V, uses xMAP ... to 100 proteins and peptides in one ... of up to 100 color-coded bead sets, ... a unique reactant (enzyme substrates, receptors, antigens, ...
Biology Products: